Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

More stories below advertisement

Latest Press Releases

Legal Marijuana Market Size Could Now Exceed $70 Billion by 2027 as Demand Rises
- PR Newswire - PRF - Thu Jul 23, 7:30AM CDT
PR Newswire - PRF - CMTX
Thu Jul 23, 7:30AM CDT
PALM BEACH,  Fla., /PRNewswire/ -- The global market for legal cannabis has been consistently rising the past couple of years and is expected to continue for the next several years according to industry market reports. The global legal marijuana market size is expected to reach USD by 2027,  published by Grand View Research, Inc. It is anticipated to expand at a CAGR of 18.1% during the forecast period. Increasing legalization of cannabis for medical as well as adult-use is expected to promote growth. The report said: "On the basis of type, the medical segment held the leading revenue share of 71.0% in 2019, owing to the growing adoption of cannabis as a pharmaceutical product for treating severe medical conditions, such as cancer, arthritis, and Parkinson's disease and Alzheimer's disease among other neurological conditions. Moreover, increasing need for pain management therapies along with growing disease burden of chronic pain among elders is expected to boost the product demand."   Active cannabis companies in the industry making moves include:  (OTCPK: MCTC), . (NASDAQ: APHA) (TSX: APHA), (NASDAQ: CRON) (TSX: CRON), (OTCQB: KAYS), (NASDAQ: NEPT) (TSX: NEPT).
Beyond Smoking: Why CBD-Based Products Could Be The Future
- MENAFN - Wed Jul 15, 10:03PM CDT
MENAFN - CMTX
Wed Jul 15, 10:03PM CDT
Beyond Smoking: Why CBD-Based Products Could be the Future
- PR Newswire - PRF - Wed Jul 15, 7:45AM CDT
PR Newswire - PRF - CMTX
Wed Jul 15, 7:45AM CDT
, /PRNewswire/ -- There may be over 34 million adult smokers in the US, but nearly 70% of those people are trying to kick the habit. Unfortunately, only a handful are ever successful, regardless if they try to quit cold turkey or by using one of the many smoking cessation therapies on the market. Luckily, another potential smoking cessation therapy is available for the 23 million people who want to quit and could be more effective than other methods. Cannabidiol (CBD) has been shown to help with chronic pain, anxiety, and , and is now also being studied for its effectiveness as a quit smoking aid. Companies like (NASDAQ: APHA) (TSX: APHA), (NYSE: ACB) (TSX: ACB), (NASDAQ: CRON) (TSX: CRON), and (NYSE: CGC) (TSX: WEED) have all developed CBD vape cartridges, but newly-listed life sciences company (CSE: TAAT) is breaking free from the vaping trend with its CBD cigarettes.
Why CBG (Cannabigerol) May Have a Promising Role to Play in FDA Drug Approvals
- PR Newswire - PRF - Tue Jul 14, 7:45AM CDT
PR Newswire - PRF - CMTX
Tue Jul 14, 7:45AM CDT
, /PRNewswire/ -- The CBD craze was a long time coming and its presently full steam ahead. 2019 was the year of cannabidiol (CBD) in the cannabis industry. CBD continued to make its way into countless consumer products, from sodas to sports bras. A on the Canna Law Blog said: "Recently, another cannabinoid has begun getting a lot of buzz inside the cannabis industry, much like CBD before it. That cannabinoid is CBG (cannabigerol). Like CBD, CBG is among the 100+ molecules in the cannabis plant. From a scientific perspective, CBG is unique for the "precursor" role it plays in synthesizing other cannabinoids–including THC and CBD–and in synthesizing the overall chemical composition of the plant. From a regulatory perspective, the legal status of CBG products may be less problematic than CBD products. It continued: "It is illegal to add CBD to many products, in FDA's view, due to the "drug exclusion rule." According to FDA, products containing CBD cannot be sold as dietary supplements because CBD was investigated and approved by FDA as a new drug (Epidoex). If something is a non-exempt "drug" it cannot be placed in the food stream under the Food Drug & Cosmetic Act. Mentioned in today's commentary include:  (NASDAQ: APHA) (TSX: APHA), (OTCPK: RTSL), (NASDAQ: CRON) (TSX: CRON), (NYSE: YCBD), (NASDAQ: VFF) (TSX: VFF).
Cronos Group Announces Completion of Continuance to British Columbia
- GlobeNewswire - Thu Jul 9, 3:30PM CDT
GlobeNewswire - CMTX
Thu Jul 9, 3:30PM CDT
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos Group" or the "Company") announces that, effective today, the Company has continued from the laws of the Province of Ontario to the laws of the Province of British Columbia (the "Continuance").The Continuance was approved by shareholders of the Company at the Company's 2020 Annual and Special Meeting of Shareholders held on June 25, 2020.
Cronos Group Inc. to Hold 2020 Second Quarter Earnings Conference Call on August 6, 2020
- GlobeNewswire - Mon Jul 6, 8:00AM CDT
GlobeNewswire - CMTX
Mon Jul 6, 8:00AM CDT
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos Group" or the "Company") will hold its 2020 Second Quarter Earnings Conference Call on Thursday, August 6, 2020 at 8:30 a.m. EDT. Cronos Group's senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks.
Cronos Group Inc. Announces Results of 2020 Annual and Special Meeting of Shareholders
- GlobeNewswire - Thu Jun 25, 4:20PM CDT
GlobeNewswire - CMTX
Thu Jun 25, 4:20PM CDT
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos Group" or the "Company") announces that at its Annual and Special Meeting of Shareholders held earlier today (the "Meeting") there were 652 shareholders voting in person or by proxy holding in total 195,124,634 common shares of the Company, representing 55.94% of the total number of common shares of the Company outstanding.
Rise In CBD and CBG's Popularity Driven By Combination Of Non-Psychoactive Nature and Therapeutic Properties
- MENAFN - Tue Jun 23, 11:04PM CDT
MENAFN - CMTX
Tue Jun 23, 11:04PM CDT
Palm Beach, FL - June 23, 2020 - The cannabis plant is made up of more than 100 unique chemical compounds, known as cannabinoids. So far, the two most common and well-known cannabinoids are tetrahydrocannabinol (THC) and cannabidiol (CBD). THC adoption is being boosted by its use in the recreational market, while CBD, thanks to its non-psychoactive nature, is quickly making its way into everything from medicines to edibles to pet food, with U.S. sales of CBD expected to top $23 billion by 2023, according to THCXIndex.com. The article stated: ''However, as most industry participants focus their attention on these two cannabinoids - which are here to stay - CBG is rapidly emerging as the third cannabinoid that deserves the attention of investors, especially those in the private equity space, thanks to its rising popularity.'' Another article from New Frontier data added: ''There''s no escaping it: Right now, CBD is in. Offering the medicinal appeal of cannabis without intoxicating effects, CBD is finding its way into virtually anything. Even after the buzz subsides and the conversation becomes more realistic and nuanced, the cannabinoid is likely to remain a staple of the health and wellness industry. Of course, THC is not going anywhere either, but they are only two of over 100 cannabinoids identified so far. Industry pros are starting to look to the horizon for what else the incredible plant has to offer. Mentioned in today''s commentary include: (NYSE: ACB) (TSX: ACB) , (OTCPK: RTSL), (NASDAQ: NEPT) (TSX: NEPT), (NASDAQ: CRON) (TSX: CRON), (OTCQB: CVSI).
Rise in CBD and CBG's Popularity Driven By Combination of Non-psychoactive Nature and Therapeutic Properties
- PR Newswire - PRF - Tue Jun 23, 7:55AM CDT
PR Newswire - PRF - CMTX
Tue Jun 23, 7:55AM CDT
, /PRNewswire/ -- The cannabis plant is made up of more than 100 unique chemical compounds, known as cannabinoids. So far, the two most common and well-known cannabinoids are tetrahydrocannabinol (THC) and cannabidiol (CBD). THC adoption is being boosted by its use in the recreational market, while CBD, thanks to its non-psychoactive nature, is quickly making its way into everything from medicines to edibles to pet food, with U.S. sales of CBD expected to top by 2023,  to THCXIndex.com. The article stated: "However, as most industry participants focus their attention on these two cannabinoids – which are here to stay – CBG is rapidly emerging as the third cannabinoid that deserves the attention of investors, especially those in the private equity space, thanks to its rising popularity."  Another  from New Frontier data added: "There's no escaping it: Right now, CBD is . Offering the medicinal appeal of cannabis without intoxicating effects, CBD is finding its way into virtually anything. Even after the buzz subsides and the conversation becomes more realistic and nuanced, the cannabinoid is likely to remain a staple of the health and wellness industry. Of course, THC is not going anywhere either, but they are only two of over 100 cannabinoids identified so far. Industry pros are starting to look to the horizon for what else the incredible plant has to offer.   Mentioned in today's commentary include:  (NYSE: ACB) (TSX: ACB) , (OTCPK: RTSL), (NASDAQ: NEPT) (TSX: NEPT), (NASDAQ: CRON) (TSX: CRON), (OTCQB: CVSI).
Cannabis Sales Turning a New Leaf Expected to Top $30 Billion Annually Within the Next Four Years
- PR Newswire - PRF - Wed Jun 17, 7:55AM CDT
PR Newswire - PRF - CMTX
Wed Jun 17, 7:55AM CDT
, /PRNewswire/ -- Cannabis companies have experienced a rapid growth phase for years. Industry reports say that the COVID-19 outbreak is causing serious jitters among large cannabis companies, with a growing list of multistate marijuana operators scaling back by laying off workers and shuttering operations in a bid to slash costs. Marijuana Business Daily said: "But as the (worldhealth crisis) worsens in the U.S. and destabilizes both the marijuana and mainstream markets, many cannabis businesses have pivoted to restructuring, eliminating inefficiencies and pulling back on plans for expansion. Marijuana Business Daily : "Coronavirus conditions are prodding cannabis companies to take even more aggressive steps to reduce expenses, lower head count and sell noncore assets in a bid to accelerate their path to profit," said , equity analyst at s Investor Intelligence.  But an in Politico sees a bright future, saying: "Coronavirus hasn't kept some cannabis companies down: They're staffing up even as unemployment in many other sectors soars… Weed businesses around the country that were in strong financial shape heading into the pandemic are hiring additional workers in response to robust demand for marijuana products. Almost all states have allowed pot shops to remain open, even though vast swaths of the retail economy have been shuttered for weeks."  Active companies in the Cannabis market this week include (OTCQB: NUGS), (NASDAQ: CRON) (TSX:CRON), (NYSE: CGC) (TSX: WEED), . (NASDAQ: OGI) (TSX: OGI), (OTCPK: MJNA).

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies